AKBA
Akebia Therapeutics, Inc.
-0.03 (-2.77%)0.89USD3.7M成交股數247M市值–本益比(近四季)1.1股價營收比-21.4%營收年增(近四季)2026-11-09下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 49.1M-14% | 53.5M+15% | 58.8M+57% | 62.5M+43% | 57.3M+76% | 46.5M+11% | 37.4M-34% | 43.6M+9% | 32.6M | 42.0M | 56.4M | 40.0M |
| 營業成本 | 10.4M | 12.3M | 9.4M | 9.9M | 7.6M | 20.4M | 14.2M | 17.0M | 11.6M | 18.0M | 17.3M | 20.2M |
| 毛利 | 38.7M-22% | 41.3M+58% | 49.4M+112% | 52.6M+98% | 49.7M+137% | 26.1M+9% | 23.3M-40% | 26.6M+34% | 21.0M | 24.0M | 39.1M | 19.8M |
| 毛利率 | 78.8% | 77.0% | 84.0% | 84.1% | 86.7% | 56.2% | 62.2% | 60.9% | 64.4% | 57.2% | 69.3% | 49.5% |
| 研發費用 | 14.1M | 14.8M | 14.9M | 11.0M | 9.8M | 11.8M | 8.5M | 7.6M | 9.7M | 13.3M | 20.2M | 19.7M |
| 銷售管理費用 | 28.2M | 30.4M | 29.1M | 26.6M | 25.7M | 27.7M | 26.5M | 26.9M | 25.4M | 22.7M | 27.0M | 25.1M |
| 營業利益 | −6.3M-147% | −4.7M-67% | 4.4M-136% | 14.1M-261% | 13.5M-190% | −14.3M+10% | −12.5M+39% | −8.7M-66% | −14.9M | −13.0M | −9.0M | −25.6M |
| 營業利益率 | -12.9% | -8.8% | 7.6% | 22.6% | 23.6% | -30.8% | -33.4% | -20.0% | -45.8% | -31.0% | -16.0% | -64.0% |
| 稅後淨利 | −8.9M-246% | −9.1M-60% | 540K-103% | 247K-103% | 6.1M-134% | −22.8M+57% | −20.0M+79% | −8.6M-68% | −18.0M | −14.5M | −11.2M | −26.9M |
| 淨利率 | -18.1% | -16.9% | 0.9% | 0.4% | 10.7% | -49.0% | -53.5% | -19.7% | -55.2% | -34.5% | -19.8% | -67.2% |
| 稀釋 EPS | -0.03-200% | -0.03-70% | 0.00-100% | 0.00-100% | 0.03-133% | -0.10+25% | -0.10+67% | -0.04-73% | -0.09 | -0.08 | -0.06 | -0.15 |
| 稀釋股數 | 270M | 267M | 274M | 271M | 242M | 211M | 210M | 210M | 205M | 188M | 187M | 185M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 156M | 163M | 166M | 137M | 113M | 51.9M | 34.0M | 39.5M | 42.0M | 46.5M | 53.6M | 57.0M |
| 應收帳款 | 53.5M | 62.5M | 66.2M | 72.8M | 61.5M | 34.4M | 32.2M | 29.8M | 26.6M | 22.6M | 19.6M | 18.7M |
| 存貨 | 13.0M | 13.0M | 18.6M | 16.7M | 19.7M | 16.2M | 20.5M | 23.9M | 25.5M | 18.4M | 20.9M | 20.4M |
| 總資產 | 350M | 363M | 364M | 346M | 310M | 221M | 207M | 220M | 225M | 235M | 254M | 281M |
| 有息負債 | 24.8M | 36.4M | 47.6M | 47.1M | 46.5M | 38.7M | 38.4M | 38.0M | 30.1M | 34.6M | 18.5M | 26.3M |
| 總負債 | 325M | 335M | 323M | 316M | 286M | 270M | 258M | 254M | 253M | 274M | 281M | 300M |
| 股東權益 | 25.0M | 27.4M | 41.6M | 29.2M | 24.6M | −49.2M | −50.4M | −33.8M | −27.3M | −39.4M | −26.8M | −19.1M |
| 負債比 | 92.8% | 92.4% | 88.6% | 91.5% | 92.1% | 122.3% | 124.3% | 115.3% | 112.1% | 116.8% | 110.6% | 106.8% |
| 淨現金(現金 − 有息負債) | 131M | 126M | 119M | 90.2M | 66.9M | 13.2M | −4.3M | 1.5M | 11.8M | 11.9M | 35.1M | 30.7M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −21.2M | – | – | −13.6M-30% | – | – | – | −19.4M | – | – | −17.5M |
| 資本支出 | – | 62K | – | – | 18K | – | – | – | 0.00 | – | – | 0.00 |
| 自由現金流 | – | −21.3M | – | – | −13.6M-30% | – | – | – | −19.4M | – | – | −17.5M |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -39.7% | – | – | -23.7% | – | – | – | -59.6% | – | – | -43.8% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 236M
| Reportable | 236M | 100.0% | +47.5% |
|---|
產品／服務2025 年度 · 236M
| Auryxia | 182M | 76.9% | +19.3% |
|---|---|---|---|
| Vafseo | 45.8M | 19.4% | – |
| License Collaboration And Other Revenue | 8.9M | 3.8% | +10.8% |
| 產品 小計 | 227M | 96.2% | +49.4% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 236M | +47.5% | −5.3M | -2.2% | -0.02 | 67.7M |
| FY2024 | 160M | -17.7% | −69.4M | -43.3% | -0.33 | −40.7M |
| FY2023 | 195M | -33.5% | −51.9M | -26.7% | -0.28 | −23.4M |
| FY2022 | 292M | +38.2% | −94.2M | -32.2% | -0.52 | −73.3M |
| FY2021 | 212M | -28.2% | −282M | -133.2% | -1.70 | −253M |
| FY2020 | 295M | -12.0% | −385M | -130.6% | -2.78 | −111M |
| FY2019 | 335M | +61.3% | −280M | -83.5% | -2.36 | −264M |
| FY2018 | 208M | – | −144M | -69.1% | -2.47 | −99.1M |